Literature DB >> 33504188

Bridging May Increase the Risk of Symptomatic Intracranial Hemorrhage in Thrombectomy Patients With Low Alberta Stroke Program Early Computed Tomography Score.

Pasquale Mordasini1, Urs Fischer2, Johannes Kaesmacher1,3, Thomas R Meinel2, Stefania Nannoni4, Marta Olivé-Gadea5, Eike I Piechowiak1, Christian Maegerlein6, Martina Goeldlin2, Laurent Pierot7, David J Seiffge2, Vitor Mendes Pereira8, Mirjam R Heldner2, Lorenz Grunder3, Vincent Costalat9, Marcel Arnold2, Tomas Dobrocky1, Jan Gralla1.   

Abstract

BACKGROUND AND
PURPOSE: Whether intravenous thrombolysis (IVT) increases the risk for symptomatic intracranial hemorrhage (sICH) in patients treated with mechanical thrombectomy (MT) is a matter of debate. Purpose of this study was to evaluate the extent of early ischemia as a possible factor influencing the risk for sICH after IVT+MT versus direct MT.
METHODS: An explorative analysis of the BEYOND-SWIFT (Bernese-European Registry for Ischemic Stroke Patients Treated Outside Current Guidelines With Neurothrombectomy Devices Using the SOLITAIRE FR With the Intention for Thrombectomy) multicenter cohort was performed. We hypothesized that the sICH risk between IVT+MT versus direct MT differs across the strata of Alberta Stroke Program Early CT Scores (ASPECTS). For this purpose, all patients with ICA, M1, and M2 vessel occlusions and available noncontrast computed tomography or diffusion-weighed imaging ASPECTS (n=2002) were analyzed. We used logistic regression analysis in subgroups, as well as interaction terms, to address the risk of sICH in IVT+MT versus direct MT patients across the ASPECTS strata.
RESULTS: In 2002 patients (median age, 73.7 years; 50.7% women; median National Institutes of Health Stroke Scale score, 16), the overall rate of sICH was 6.5% (95% CI, 5.5%-7.7%). Risk of sICH differed across ASPECTS groups (9-10: 6.3%; 6-8: 5.6% and ≤5 9.8%; P=0.042). With decreasing ASPECTS, the risks of sICH in the IVT+MT versus the direct MT group increased from adjusted odds ratio of 0.61 ([95% CI, 0.24-1.60] ASPECTS 9-10), to 1.72 ([95% CI, 0.69-4.24] ASPECTS 6-8) and 6.31 ([95% CI, 1.87-21.29] ASPECTS ≤5), yielding a positive interaction term (1.91 [95% CI, 1.01-3.63]). Sensitivity analyses regarding diffusion-weighed imaging versus noncontrast computed tomography ASPECTS did not alter the primary observations.
CONCLUSIONS: The extent of early ischemia may influence relative risks of sICH in IVT+MT versus direct MT patients, with an excess sICH risk in IVT+MT patients with low ASPECTS. If confirmed in post hoc analyses of randomized controlled trial data, IVT may be administered more carefully in patients with low ASPECTS eligible for and with direct access to MT.

Entities:  

Keywords:  brain infarction; hemorrhage; ischemic stroke; thrombectomy; tissue-type plasminogen activator

Mesh:

Substances:

Year:  2021        PMID: 33504188     DOI: 10.1161/STROKEAHA.120.030508

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  3 in total

1.  Safety and Efficacy of Intravenous Alteplase before Endovascular Thrombectomy: A Pooled Analysis with Focus on the Elderly.

Authors:  Asaf Honig; Hen Hallevi; Naaem Simaan; Tzvika Sacagiu; Estelle Seyman; Andrei Filioglo; Moshe J Gomori; Ofer Rotschild; Tali Jonas-Kimchi; Udi Sadeh; Anat Horev; Ronen R Leker; José E Cohen; Jeremy Molad
Journal:  J Clin Med       Date:  2022-06-26       Impact factor: 4.964

2.  Bridging intravenous thrombolysis in patients with atrial fibrillation.

Authors:  Adnan Mujanovic; Christoph C Kurmann; Tomas Dobrocky; Marta Olivé-Gadea; Christian Maegerlein; Laurent Pierot; Vitor Mendes Pereira; Vincent Costalat; Marios Psychogios; Patrik Michel; Morin Beyeler; Eike I Piechowiak; David J Seiffge; Pasquale Mordasini; Marcel Arnold; Jan Gralla; Urs Fischer; Johannes Kaesmacher; Thomas R Meinel
Journal:  Front Neurol       Date:  2022-08-03       Impact factor: 4.086

3.  Efficacy and safety of bridging thrombolysis initiated before transfer in a drip-and-ship stroke service.

Authors:  Jan Christoph Purrucker; Miriam Heyse; Simon Nagel; Christoph Gumbinger; Fatih Seker; Markus Möhlenbruch; Peter Arthur Ringleb
Journal:  Stroke Vasc Neurol       Date:  2021-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.